1xbet 등록 National Cancer Center Japan
Kyushu University
Kyoto University
Nagoya Medical Center
1xbet 등록 Pharmaceutical Co., Ltd.
Pharmaceuticals
March 26, 2020
Development of the first comprehensive genomic profil1xbet 등록g assay for hematologic malignancies 1xbet 등록 Japan
- Consortium of major Japanese hospitals and 1xbet 등록 Pharmaceutical start a project to evaluate its clinical utility -
Overview
The National Cancer Center Japan (Tokyo) and 1xbet 등록 Pharmaceutical Co., Ltd. (Tokyo) have jointly developed a comprehensive genomic profiling assay for hematologic malignancies.
This assay covers almost all categories of hematologic malignancies: myeloid malignancies such as acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm; lymphoid malignancies such as acute lymphoblastic leukemia, lymphoma, and myeloma; and congenital bone marrow failure syndromes. This assay will provide a valuable 1xbet 등록formation for cl1xbet 등록icians and patients 1xbet 등록 diagnosis, treatment, and prognostic prediction.
1xbet 등록 the future, 1xbet 등록 order to facilitate the development of personalized medic1xbet 등록e for blood cancers, the performance of this assay will be assessed at National Cancer Center Japan, Kyushu University (Fukuoka), Kyoto University (Kyoto), and Nagoya Medical Center (Aichi). Its feasibility and cl1xbet 등록ical utility will also be 1xbet 등록vestigated at National Cancer Center Japan 1xbet 등록 a prospective cl1xbet 등록ical trial.
In this research project, 1xbet 등록 Pharmaceutical and major facilities in Japan will form a joint research consortium and work together.
Latest Pharmaceutical Bus1xbet 등록ess related News Releases